SHANGHAI ZJ BIO-TECH CO., LTD Shanghai ZJ Bio-Tech Co., Ltd Share Price
Equities
688317
CNE100005DB6
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.25 CNY | -1.52% |
|
-2.29% | -22.55% |
| Sales 2022 | 2.33B 322M 25.43B | Sales 2023 | 274M 38.01M 3B | Capitalization | 4.03B 559M 44.06B |
|---|---|---|---|---|---|
| Net income 2022 | 760M 105M 8.31B | Net income 2023 | -137M -18.98M -1.5B | EV / Sales 2022 | 1.41 x |
| Net cash position 2022 | 3.14B 435M 34.31B | Net cash position 2023 | 2.76B 383M 30.19B | EV / Sales 2023 | 4.63 x |
| P/E ratio 2022 |
8.5
x | P/E ratio 2023 |
-29.5
x | Employees | 435 |
| Yield 2022 |
3.59% | Yield 2023 |
-
| Free-Float | 55.92% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.52% | ||
| 1 week | -2.29% | ||
| Current month | +1.06% | ||
| 1 month | +11.15% | ||
| 3 months | +3.70% | ||
| 6 months | -29.96% | ||
| Current year | -22.55% |
1 week
16.07
17.23
1 month
13.7717.23
Current year
12.5821.20
1 year
12.5828.32
3 years
12.5879.36
5 years
12.5893.80
10 years
12.5893.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Bin Shao
CEO | Chief Executive Officer | 53 | 17/04/05 |
Wei Qin Ni
DFI | Director of Finance/CFO | 43 | 31/03/05 |
Yi Yun Wang
PRN | Corporate Officer/Principal | 44 | 30/06/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Sheng Yu
BRD | Director/Board Member | 55 | 21/05/20 |
Xue Yao Li
BRD | Director/Board Member | 47 | 21/05/20 |
Jun Bin Shao
CEO | Chief Executive Officer | 53 | 17/04/05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +5.62% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 16.25 | -1.52% | 1 833 856 |
| 15/05/24 | 16.5 | +1.10% | 2,921,816 |
| 14/05/24 | 16.32 | +0.55% | 1,560,219 |
| 13/05/24 | 16.23 | -0.67% | 2,015,126 |
| 10/05/24 | 16.34 | -2.39% | 1,802,660 |
End-of-day quote Shanghai S.E., May 15, 2024
More quotes
Shanghai ZJ Bio-Tech Co Ltd is a China-based company that mainly engaged in the production of molecular diagnostic reagents. The Company is mainly engaged in the research, development, production and sales of genetic diagnostic reagents and equipment. The Company's main products include nucleic acid detection kits and molecular diagnostic instruments. The Company's products are mainly used in areas such as emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. The Company mainly conducts business within the domestic market.
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -22.55% | 439M | |
| -4.57% | 12.32B | |
| -4.35% | 8.1B | |
| +8.91% | 5.87B | |
| +30.77% | 5.52B | |
| -7.42% | 4.29B | |
| -54.04% | 3.16B | |
| +14.44% | 2.72B | |
| -2.21% | 2.37B | |
| +28.21% | 2.23B |
- Stock Market
- Equities
- 688317 Stock
